Brenda Cordell is a senior healthcare consultant in the Indianapolis Health Practice of Milliman. She joined the firm in 2008 and is a lead in Milliman's life sciences consulting group. Brenda is also co-creator of Milliman DNA Gene and Cell Therapy Forecasting (Milliman DNA), a dynamic, web-based application that estimates the associated costs and cases for approved and pipeline gene and cell therapies.
Since 2016 Brenda's consulting focus has been gene and cell therapy in the areas of market access and economic value.
Brenda leads the clinical, market, and economic research that form the baseline assumptions in Milliman DNA and its associated research repository. With over 25 years of experience in leadership roles within life sciences companies and at Milliman, Brenda's focus areas are market access, payer strategy, market intelligence, and financial analysis specifically in rare disease and novel therapies.
Brenda has authored several white papers and reports, some of which have been published by the Journal of Managed Care & Specialty Pharmacy (JMCSP). She has also presented at AMCP, Self-Insurance Institute of America (SIIA), and other conferences. She is a member of the SIIA Cell & Gene Therapy Task Force.